2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Process – High Priority Description Percentage of female patients aged 18 to 70 withContinue reading “2024 MIPS Measure #450: Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer”
MIPS/CQM Archive
2024 MIPS Measure #451: RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Process Description Percentage of adult patients (aged 18 or over) with metastatic colorectal cancerContinue reading “2024 MIPS Measure #451: RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy”
2024 MIPS Measure #452: Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Process – High Priority Description Percentage of adult patients (aged 18 or over) withContinue reading “2024 MIPS Measure #452: Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies”
2024 MIPS Measure #387: Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Process Description Percentage of patients, regardless of age, who are active injection drug usersContinue reading “2024 MIPS Measure #387: Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users”
2024 MIPS Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Outcome – High Priority Description Percentage of patients aged 18 years and older whoContinue reading “2024 MIPS Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction”
2024 MIPS Measure #392: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Outcome – High Priority Description Rate of cardiac tamponade and/or pericardiocentesis following atrial fibrillationContinue reading “2024 MIPS Measure #392: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation”
2024 MIPS Measure #393: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Outcome – High Priority Description Infection rate following CIED device implantation, replacement, or revision.Continue reading “2024 MIPS Measure #393: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision”
2024 MIPS Measure #394: Immunizations for Adolescents
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Process Description The percentage of adolescents 13 years of age who had one doseContinue reading “2024 MIPS Measure #394: Immunizations for Adolescents”
2024 MIPS Measure #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Process – High Priority Description Pathology reports based on lung biopsy and/or cytology specimensContinue reading “2024 MIPS Measure #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)”
2024 MIPS Measure #396: Lung Cancer Reporting (Resection Specimens)
2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) MEASURE TYPE: Process – High Priority Description Pathology reports based on lung resection specimens with aContinue reading “2024 MIPS Measure #396: Lung Cancer Reporting (Resection Specimens)”